Cancer immunotherapy: potential involvement of mediators
The description of a cell-free soluble anti-tumour factor by Carswell et al. in 1975 (Proc Natl Acad Sci USA, 72: 3666–3670) was followed by a long series of experimental and clinical investigations into the role of cell-free mediators in cancer immunotherapy. These investigations included research...
Saved in:
| Main Author: | S. Ben-Efraim |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1997-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1080/09629359791659 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
by: Kazuya Matsumoto, et al.
Published: (2025-03-01) -
Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy
by: Yue Peng, et al.
Published: (2025-08-01) -
Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
by: Liza Eiman, et al.
Published: (2025-08-01) -
Recent Progress and Potential of G4 Ligands in Cancer Immunotherapy
by: Jiahui Lin, et al.
Published: (2025-04-01) -
STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
by: Laura Gehrcken, et al.
Published: (2025-05-01)